Why the study?
Cardiovascular-renal-hepatic-metabolic syndrome (CRHMS) is an emerging concept of interconnected multiorgan dysfunction driven by shared risk factors and pathophysiological mechanisms, requiring a synthesis of current evidence on phenotypes, staging, screening, risk stratification, and multimodal management.
Answers are grounded in this paper and cite their sources.
This narrative review synthesizes the emerging concept of cardiovascular-renal-hepatic-metabolic syndrome (CRHMS), integrating phenotypic classification (Russian consensus) with international staging (stages 0–IV) to guide individualized multiorgan screening and early protective management.
Cardiovascular-renal-hepatic-metabolic syndrome (CRHMS) is an emerging concept describing the interconnected dysfunction of the cardiovascular system, kidneys, liver, and metabolic organs driven by shared risk factors and common pathophysiological mechanisms. Aim. To summarize current evidence regarding phenotypes, staging, screening strategies, risk stratification, and multimodal management of CRHMS. A narrative literature review was conducted using publications indexed in PubMed, Google Scholar, and eLibrary.ru between 2016 and 2026, supplemented by seminal earlier studies and current international and Russian consensus documents. The principal mechanisms underlying multiorgan injury include adipose tissue dysfunction, insulin resistance, chronic low-grade inflammation, oxidative stress, endothelial dysfunction, neurohormonal activation, microvascular impairment, and progressive fibrosis. According to the Russian consensus, CRHMS has lipocentric, glucocentric, hypertensive, dyslipidemic, nephrocentric, hepatocentric, and mixed phenotypes. The international staging model categorizes the syndrome into stages 0–IV, ranging from the absence of risk factors to established cardiovascular disease with multiorgan involvement. Integrating phenotypic and stage-based assessment enables individualized screening, including evaluation of anthropometric parameters, glucose and lipid metabolism, kidney function (estimated glomerular filtration rate and albuminuria), liver fibrosis, and markers of subclinical cardiovascular damage. Management should begin at the earliest stages of disease and combine lifestyle modification with cardio-, reno-, hepato-, and metabolically protective interventions aimed at preventing progression of multiorgan dysfunction and reducing the risks of cardiovascular events, chronic kidney disease, and other adverse clinical outcomes.
No takes yet. Share an insight, caveat, or question.
GAVRILOVA et al. (2026) conducted a review in Cardiovascular-renal-hepatic-metabolic syndrome (CRHMS). Phenotype- and stage-guided multimodal cardiometabolic, renal, and hepatic management was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: